[1] BONACQUISTI E E, NGUYEN J. Connexin 43 (Cx43) in cancer: Implications for therapeutic approaches via gap junctions[J]. Cancer Lett,2019,442:439-444. doi:  10.1016/j.canlet.2018.10.043
[2] ZHANG X H, SUN Y, WANG Z Y, et al. Up-regulation of connexin-43 expression in bone marrow mesenchymal stem cells plays a crucial role in adhesion and migration of multiple myeloma cells[J]. Leuk Lymphoma,2015,56(1):211-218. doi:  10.3109/10428194.2014.913289
[3] ZHANG Y M, WANG Z Y, ZHANG L Y, et al. Impact of connexin 43 coupling on survival and migration of multiple myeloma cells[J]. Arch Med Sci,2017,13(6):1335-1346.
[4] JAKUBIKOVA J, CHOLUJOVA D, HIDESHIMA T, et al. A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications[J]. Oncotarget,2016,7(47):77326-77341. doi:  10.18632/oncotarget.12643
[5] GAO M J, KONG Y Y, YANG G, et al. Multiple myeloma cancer stem cells[J]. Oncotarget,2016,7(23):35466-35477. doi:  10.18632/oncotarget.8154
[6] BEHRENS J, KAMERITSCH P, WALLNER S, et al. The carboxyl tail of Cx43 augments p38 mediated cell migration in a gap junction-independent manner[J]. Eur J Cell Biol,2010,89(11):828-838. doi:  10.1016/j.ejcb.2010.06.003
[7] BELLONI D, HELTAI S, PONZONI M, et al. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment[J]. Haematologica,2018,103(4):707-716. doi:  10.3324/haematol.2017.167486
[8] XU S, DE VEIRMAN K, DE BECKER A, et al. Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target? Leukemia,2018,32(7):1500-1514. doi:  10.1038/s41375-018-0061-9
[9] ISSA M E, CRETTON S, CUENDET M. Targeting multiple myeloma cancer stem cells with natural products - lessons from other hematological malignancies[J]. Planta Med,2017,83(9):752-760. doi:  10.1055/s-0043-109558
[10] WANG Z Y, YUAN Y Q, ZHANG L Y, et al. Impact of cell fusion in myeloma marrow microenvironment on tumor progression[J]. Oncotarget,2018,9(57):30997-31006. doi:  10.18632/oncotarget.25742